Back to Newsroom

Endocyte and Nihon Medi-Physics (NMP) Enter Into Exclusive License Agreement to Develop and Commercialize Companion Imaging Diagnostic Etarfolatide for Cancer in Japan

WEST LAFAYETTE, Ind. and TOKYO, Sept. 5, 2013 — Endocyte, Inc. (Nasdaq: ECYT), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, and Nihon Medi-Physics (NMP), a market leader in the development, production and distribution of radiopharmaceuticals for nuclear medicine procedures in Japan, today announced that they have entered into a license and commercialization agreement.